Overexpression of MTFR2 Predicts Poor Prognosis of Breast Cancer.
Overexpression of MTFR2 Predicts Poor Prognosis of Breast Cancer.
复制标题
MTFR2过度表达预示乳腺癌预后不良。
DOI：
10.2147/cmar.s272088
复制
发表时间：
2020
影响因子：
3.3
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Lu W;Zang R;Du Y;Li X;Li H;Liu C;Song Y;Li Y;Wang Y
线粒体裂变调节因子2（MTFR 2）已被报道可促进肿瘤的增殖、迁移和侵袭;然而，对其在乳腺癌中的功能知之甚少。因此，我们研究了MTFR 2表达对乳腺癌预后的影响。采用免疫组化法检测乳腺癌组织中MTFR 2的表达，采用Log rank检验和考克斯模型评价总生存期（OS）和无复发生存期（RFS）。MTFR 2表达与临床分期（P<0.001）、T分期（P=0.005）、N分期（P=0.001）、M分期（P= 0.041）、HER 2表达（P= 0.001）和分子亚型（P=0.002）显著相关。MTFR 2高表达组的OS和RFS均明显短于MTFR 2低表达组（P均< 0.001）。单因素和多因素分析均显示MTFR 2是乳腺癌患者OS（HR，2.8，95%CI 1.1-6.8，P = 0.023）和RFS（HR，2.8，95%CI 1.2-6.4，P = 0.015）的独立预后因素。此外，在HER 2阳性和TNBC亚型中，MTFR 2高表达与OS和RFS差之间的关联更明显。综上所述，我们的结果表明，MTFR 2高表达与乳腺癌患者的预后不良相关，并且这种关联在侵袭性肿瘤患者中更为明显。因此，MTFR 2表达可能是乳腺癌患者潜在的重要预后生物标志物和临床靶点。
Mitochondrial fission regulator 2 (MTFR2) has been reported to promote proliferation, migration and invasion in tumors; however, little is known about its function in breast cancer. Thus, we investigated the effect of MTFR2 expression on prognosis of breast cancer. The expression of MTFR2 in breast cancer tissues was detected by immunohistochemistry, and overall survival (OS) and recurrence free survival (RFS) were evaluated by the Log rank test and Cox model. We found that MTFR2 expression was significantly associated with clinical stage (P<0.001), T classification (P=0.005), N classification (P=0.001), M classification (P=0.041), HER2 expression (P= 0.001), and molecular subtypes (P=0.002), respectively. Compared with low MTFR2 expression, the patients with higher expression of MTFR2 exhibited significantly shorter OS and RFS (All P < 0.001). Both univariate and multivariate analyses showed that MTFR2 was an independent prognostic factor for OS (HR, 2.8, 95% CI 1.1–6.8, P = 0.023) and RFS (HR, 2.8, 95% CI 1.2–6.4, P = 0.015) in breast cancer patients. Moreover, in HER2 positive and TNBC subtype, the associations between high MTFR2 expression and poor OS and RFS were more pronounced. Taken together, our results demonstrated that high MTFR2 expression was associated with poor prognosis of breast cancer patients, and such an association was more pronounced in the patients with aggressive tumors. Therefore, MTFR2 expression might be a potentially important prognostic biomarker and clinical target for patients with breast cancer.